Inhibrx stock soars after positive cancer drug trial results
PositiveFinancial Markets

Inhibrx's stock has surged following promising results from its latest cancer drug trial, signaling potential breakthroughs in cancer treatment. This is significant not only for investors but also for patients seeking new therapies, as successful trials can lead to faster approvals and wider access to innovative treatments.
— Curated by the World Pulse Now AI Editorial System












